Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides
about
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cellsAmplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNARegulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-mybIn vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotidesNovel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell linesMyb targeted therapeutics for the treatment of human malignancies.Generation and repair of AID-initiated DNA lesions in B lymphocytes.Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.Targeted therapies for the myeloid leukaemias.Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamideComparison and evaluation of gene therapy and epigenetic approaches for wound healing.Progress in adult acute lymphoblastic leukemia.Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycolGene therapy for paediatric leukaemia.EgoNet: identification of human disease ego-network modulesBCR-ABL as a target for novel therapeutic interventions.DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.Antisense strategies to characterize the role of genes and oncogenes involved in myeloid differentiation.Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy.The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention.The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers.The rat gene homologous to the human gene 9-27 is involved in the development of the mammary gland.Electroporation enhances c-myc antisense oligodeoxynucleotide efficacyGrowth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide.erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides.Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenesGenetic dissection of dome formation in a mammary cell line: identification of two genes with opposing action.Murine hematopoietic reconstitution after tagging and selection of retrovirally transduced bone marrow cellsT-cell immunity to the joining region of p210BCR-ABL proteinNormal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.Role of the KIT protooncogene in normal and malignant human hematopoiesisA 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.Cancer induction by restriction of oncogene expression to the stem cell compartment
P2860
Q24313109-8FC95A76-ABAF-4500-BC1A-58B77B503486Q24568308-2AB8478C-6CBE-489D-963C-B21739708E57Q24680464-A059A2FB-F359-4A83-9FC3-848C28012C6FQ27477597-D88795DF-187B-4538-BBE8-969E5C3333E9Q27824789-1C619BBC-BD74-4DCC-9347-CC5495A42453Q28469349-9960A245-212A-4474-AED2-9706922B81E6Q33667372-D93B7DAE-1A9C-4720-96C7-F2BE078049EBQ33690522-421F3830-F857-4FCE-9DCA-D9CD0B2E944AQ33701925-1AA75ADA-92BF-410E-B212-3F9EBF33F952Q34074884-FE134B03-BDA3-43A4-B3D7-97201611A329Q34111303-F5E4BFDC-3621-417A-8924-D5B7C1DEEA2FQ34156763-49F6D344-A261-4058-A148-164D22F2CCB1Q34182886-3913EC20-1B8B-4582-B99D-0530A6D6B52DQ34433380-A560AD0A-2841-475B-B8BB-0AB113A35F79Q34451905-43808712-FE5E-49DD-B577-9D901990F440Q34525552-4D3F6510-39F3-496B-B917-5EDEB688AECCQ34568971-E559E57D-6545-4577-8880-AD542CBD9804Q34733743-6F2D52B8-FEA0-4172-A065-5DDCB03AFB55Q35022511-E0A9D417-1341-4BB5-8227-4380EB4E07EAQ35128883-1BE99744-6974-410D-80C7-5A3A305392E4Q35166848-A26D5897-7DDA-4B95-BBF7-92C86410810EQ35237895-A049C4A4-A415-4B2D-AE4E-8B7B6ED5AEA2Q35241663-AEA84531-74A1-4962-B5F3-3E7CFE9CC679Q35241689-A07045A3-FD90-470A-A259-E148A4C3C6E5Q35276631-B7EFB094-A01D-4D66-BE32-68B887550FBCQ35367235-0CA82894-0600-46DB-9F14-08F2C7F57D27Q35790794-52395FCC-2D43-46EA-9D07-CE15B413F743Q35858474-3255B8EE-6087-456B-966C-2BFDF29DD74EQ35932777-0F8B0C94-BF17-459C-9F27-03FC895F61CFQ36080272-035F2D3D-B7FB-4477-A55A-E2A6D1B3D1D5Q36303128-BB0804D1-DD2A-444F-B6A6-DD65203A8FA9Q36363202-D1998DE4-B2E9-4B72-8831-B6D12D91F7AEQ36365540-CCA3841E-5634-4B6B-9643-824420851C29Q36701345-ADE019A5-89FB-483E-85F1-69251B50F69AQ36723141-0C39AE19-F9BB-41DE-82B6-4A81D73E2C22Q36842134-063DD947-200C-4D2A-A6FC-0032A3843958Q36851400-7A4409F3-366D-43B1-A3AF-F76DF89B8EB4Q36855012-5CC6164E-6D72-412E-9A06-AD2AECF0FA97Q36963802-4B868807-B233-4E1D-831A-6657410D68ABQ37010433-3BAF74CB-DCF8-40E4-B8AF-DFCB1EEAA46C
P2860
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@ast
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@en
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@nl
type
label
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@ast
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@en
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@nl
prefLabel
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@ast
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@en
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@nl
P2093
P356
P1433
P1476
Selective inhibition of leukem ...... ntisense oligodeoxynucleotides
@en
P2093
A M Gewirtz
B Calabretta
C Szczylik
D Venturelli
L Malaguarnera
L Manzella
N C Nicolaides
P356
10.1126/SCIENCE.1857987
P407
P577
1991-08-02T00:00:00Z